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Poly ( e- caprolactone) (PCL ). Each of the polymeric nano
particles has a maximum dimension of about 300 nm to
about 500 nm , and the polymeric nanoparticles have an

SYSTEMS AND METHODS FOR

ENDOTOXIN REMOVAL FROM FLUIDS

endotoxin removal capacity of at least about 1x10° endo

CROSS -REFERENCE TO RELATED
APPLICATIONS

5 toxin units per gram of polymeric nanoparticle (EU /g ) and
an endotoxin removal efficacy of at least 1x10° endotoxin
This application claims priority to U .S . Provisional Appli - units per cm ? of nanoparticle surface area ( EU /cm²).
cation Ser. No. 62/ 178 ,647 entitled “ POLYMERIC NANO
BRIEF DESCRIPTION OF THE SEVERAL
PARTICLES FOR DRUG DELIVERY AND BACTERIAL

TOXIN REMOVAL ,” filed Apr. 15 , 2015 , the disclosure of 10
which is hereby incorporated by reference as if set forth in
its entirety herein .

FIELD

Systems and methods are provided for the removal of

The present invention is described in detail below with
FIG . 1 is a schematic depiction of an exemplary phase
15 separation
system for making polymeric nanoparticles ,
reference to the attached drawing figures, wherein :

according to an aspect of the invention ;
FIG . 2 is a schematic depiction of an endotoxin removal

endotoxins from fluids.

BACKGROUND
Antigenic responses to gram -negative bacterial infec
tions, gram - positive bacterial infections, fungal infections.
and/ or parasite infections in human beings can be stimulated
by endotoxins released from bacterial or other cell mem -

20

branes when the cell membranes are ruptured through pro - 25

cesses such as enzymatic reactions. The release of such

endotoxins may trigger sepsis or septic shock in patients,
which can lead to organ failure and /or death .

SUMMARY

In one aspect , an endotoxin removal system is provided .
The endotoxin removal system includes a plurality of poly

VIEWS OF THE DRAWINGS

system , according to an aspect of the invention ;
FIG . 3 is a schematic depiction of another endotoxin

removal system , according to an aspect of the invention ;

FIG . 4 is a transmission electron microscopy image of a
sample of polymeric nanoparticles as described in Example
2 , according to an aspect of the invention ;

FIG . 5A is a graph of the size distribution by intensity for

a sample of polymeric nanoparticles as measured by
dynamic light scattering as described in Example 2 , accord
ing to an aspect of the invention ;
FIG . 5B is a graph of the zeta potential distribution for a

30 sample of polymeric nanoparticles as measured by dynamic

light scattering as described in Example 2 , according to an

aspect of the invention ;
FIG . 6 is a graph of the florescence intensity of BODIPY
meric nanoparticles. Each polymeric nanoparticle of the Cadaverine
) as a function of endotoxin concentration as
plurality of polymeric nanoparticles has a maximum dimen - 35 described in(BCExample
3 , according to an aspect of the
sion between 300 nm and 500 nm . The endotoxin removal

;
system also includes a support member associated with the invention
FIG
.
7
is a graph showing the percent endotoxin removal
plurality of polymeric nanoparticles, where , when an aque
as a function of the concentration of polymeric nanoparticles
ous solution including endotoxin molecules is exposed
to
the
as described in Example 3 , according to an aspect of the
endotoxin removal system , the support memberor and
and the
the 4040 as
plurality of polymeric nanoparticles are cooperatively con invention ;

FIGS. 8A and 8B are transmission electron microscopy
figured to separate at least a portion of the endotoxin
molecules from the aqueous solution . Each polymeric nano - images showing endotoxins bound to the polymeric nano
particle of the plurality of polymeric nanoparticles has an
particles as described in Example 5 , according to an aspect
endotoxin removal capacity of at least 1x10° endotoxin units 45 of the invention ;
per gram of polymeric nanoparticle (EU / g ).
FIG . 9A is graph of a zeta potential distribution measure
In another aspect, a method for removing endotoxins from
ment for an endotoxin sample as described in Example 5 ,
an aqueous solution is provided . The method includes
according to an aspect of the invention ;
exposing an aqueous solution including endotoxin mol FIG . 9B is a graph of a zeta potential distribution mea
ecules to polymeric nanoparticles so that at least a portion of 50 surement for the endotoxin sample in FIG . 9A compared to

the endotoxin molecules bind to an exterior surface of one
or more of the polymeric nanoparticles to form endotoxin

a zeta potential distribution measurement for the endotoxin

sample after binding to a predetermined concentration of
polymeric
nanoparticles as described in Example 5 , accord
particles has a maximum dimension of about 300 nm to ing to an aspect of the invention ;
about 500 nm . Each of the polymeric nanoparticles have an 55 FIG . 10A is a graph showing the fluorescence intensity of
endotoxin removal capacity of at least 1x10 endotoxin units BODIPY
a function of endotoxin concentration , accord
per gram of polymeric nanoparticle (EU /g ). Themethod also ing to an asaspect
of the invention ;
includes removing at least a portion of the aqueous solution
FIG . 10B is a graph showing the fluorescence intensity of
from the endotoxin - bound polymeric nanoparticles.
In yet another aspect, a method for removing endotoxins 60 €BODIPY as a function of 1,4 C - 1,4 bis polymer concentra
from an aqueous solution is provided. The method includes tion , according to an aspect of the invention;
bound polymeric nanoparticles . Each of the polymeric nano

exposing an aqueous solution including endotoxin mol-

FIG . 10C is a graph showing the fluorescence intensity of

ecules to polymeric nanoparticles so that at least a portion of

BODIPY as a function of EGDE - 3 ,3 'polymer concentration ,

the endotoxin molecules bind to an outer surface of one or according to an aspect of the invention ;
more of the polymeric nanoparticles to form endotoxin - 65 FIG . 10D is a graph showing the fluorescence intensity of

bound polymeric nanoparticles, where at least the outer B ODIPY as a function of PCL nanoparticle concentration ,
surface of each of the polymeric nanoparticles includes according to an aspect of the invention ; and

US 9,918 ,943 B2
FIG . 10E is a graph showing the fluorescence intensity of
BODIPY as a function of polyethyleneimine polymer con centration , according to an aspect of the invention .
DETAILED DESCRIPTION

In various aspects, an endotoxin removal system and

The endotoxin removal system and methods disclosed
herein solve one or more of the above problems. The
methods and systems described herein have shown to be
much more efficient than the known methods for endotoxin
5 removal . For example, the methods and systems disclosed
herein include the synthesis and use of polymeric nanopar
ticles to efficiently sequester and /or bind endotoxins from

methods for removing endotoxins from various fluids are
disclosed . In certain aspects , the endotoxin removal system

contaminated fluids. In certain aspects , the polymeric nano
particles can have an endotoxin removal capacity of at least

endotoxins present in an aqueous solution . In one or more
aspects, the polymeric nanoparticles can be associated with

particle ( EU /g ), which is several orders ofmagnitude higher
than that of current commercially available endotoxin

can include polymeric nanoparticles capable of binding to 10 about 1x10° endotoxin units per gram of polymeric nano

a support member, such as a film or beads, which can be removal systems, such a porous silica gel matrix . As used
used together to filter an aqueous solution and remove is herein , endotoxin units (EU ) refers to 0 . 1 to 0 .2 nanograms
endotoxin present in the solution .
of endotoxin per mL . In the same or alternative aspects , the
The control of microbial infections is important for the polymeric nanoparticles can exhibit an endotoxin removal

preparation of biological media including water, in order to

prevent or reduce the number of deaths claimed by septic

efficacy of at least 1x106 EU per unit surface area (cm²) of

the polymeric nanoparticles , which is about an order of

shock or sepsis . This is particularly important because sepsis 20 magnitude higher than commercially available hydrophobic
is one of the leading causes of death around the world with
an incidence estimated to be 18 million cases per year with

charged microporous membranes.
In one or more aspects, the polymeric nanoparticles

0 .75 million cases in the U .S . alone, with this number being

disclosed herein can bind to endotoxins from various types

higher in areas where clean water sources are not readily
of bacteria , such as Gram -negative and/ or Gram - positive
available . Additionally , sepsis is a common occurrence in 25 bacteria . In one aspect, the polymeric nanoparticles can bind
clinical and hospital settings and more than half a million
to an endotoxin from one or more Gram - negative bacterial

patients are affected every year. Sepsis can be caused by both

species . In such aspects , the one or more Gram -negative

more common organisms responsible include , for example :

bacterial species includes E . coli.

Gram -positive and Gram -negative bacteria and some of the

In various aspects, the polymeric nanoparticles can

Escherichia coli (E . coli), Pseudomonas aeruginosa , 30 include
inc
or more polymers . In certain aspects, the poly
Chlamidya , Staphyloccocus, Listeria , and Streptococcus . mer can one
be
any
polymer that includes an aliphatic region or
The bacterial cell membranes of these microorganisms can
that can hydrophobically interact with one or more
release negatively or positively charged endotoxins , respec moiety
to bind the endotoxin (s ) to the polymeric nano
tively, depending on whether they are Gram -negative or endotoxins
. In the same or alternative aspects , the polymer can
Gram -positive bacteria, when damaged . When the bacterial 3535 particle
par
cell membranes are damaged by, for example, enzymatic be a polymer that includes an ionic region or moiety that can
interact with oneormore endotoxins to bind
reactions, the endotoxins released , may cause a host of the
elelectrostatically
endotoxin (s ) to the polymeric nanoparticle . In one
antigenic and inflammatory responses , in for example , a
aspect, the polymer can include both ionic and aliphatic
human body .
One way to prevent bacterial infections is by removing 40 regions that are configured to interact with one or more
the bacteria from the different sources , such as water.

endotoxins via electrostatic interactions and via hydropho

Various methods including distillation , ethylene oxide treatment, filtration , and irradiation have been employed to

bic interactions to bind the endotoxin ( s ) to the polymeric
nanoparticle .

remove endotoxins from contaminated fluids, somemethods

A non - limiting list of exemplary polymers that can be

selectivity and a low endotoxin binding ability , therefore , the
overall efficiency of endotoxin removal of these methods

poly ( acrylic acid ) (PAA ), poloxamers, polyethylene oxide
(PEO ), polyethylene glycol (PEG ), and polyflutamic acid . In

being more efficient than others . These methods are mainly 45 included in the polymeric nanoparticles includes polyesters ,
based on adsorption , filtration , ionic interactions , and phase such as Poly ( e - caprolactone ) (PCL ), polylactic acid (PLA ),
separation techniques. However, these methods have poor
Poly (lactic - co - glycolic acid (PLGA ), hyaluronic acid (HA ),
remains low . In other words, these methods are not efficient 50 certain aspects, the polymer can be biodegradable . By using

in decreasing the endotoxin levels in a fluid to lower than
0 .05 ng/ml (0 .5 endotoxin units/ml), which is the safest
exposure level to endotoxins, as determined by the U . S .
Food and Drug Administration .

a biodegradable or a biocompatible polymer, environmental
benefits can be provided in addition to a significant reduc
tion of undesired bacterial toxicity , via endotoxin removal

have been used to remove endotoxins from protein solu tions . In this method , proteins elute quickly due to their large
size , while endotoxins diffuse into the particle pores and are

biological media or components that suffer from microbial
contaminations.
In certain aspects , when the polymeric nanoparticles

retained inside the microspheres. However, the adsorption

comprises a polyester, the polyester can be characterized as

from a fluid . Such considerations are of great importance for

Polylysine immobilized cellulose porous microspheres 55 both water purification and treatment of other types of

kinetics of these microspheres is slow making it a time 60 an aliphatic polyester. An aliphatic polyester as used herein

consuming process to achieve a safe endotoxin concentra -

refers to a polyester having an aliphatic region that is

are highly polydisperse , making it difficult to have a pre -

another molecule, such as an endotoxin .

tion level of 0 .05 ng/ml. Additionally , these microspheres

capable of engaging in hydrophobic interactions with

dictable efficiency when used repetitively. Other endotoxin
In one or more aspects, the polymeric nanoparticles can
removal methods suffer from a low elute volume, poor 65 comprise , consist essentially of, or consist of one or more
selectivity, poor efficiency , filtration fouling, and /or are biodegradable polymers . In certain aspects , the polymeric
nanoparticles can comprise , consist essentially of, or consist
economically unviable .
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of one or more polyesters . In one aspect, the polymeric
nanoparticles can comprise, consist essentially of, or consist
of PCL .

In various aspects, the outer surface of the polymeric
nanoparticles can comprise , consist essentially of, or consist 5
of: one or more biodegradable polymers . In certain aspects,
the outer surface of the polymeric nanoparticles can com
prise, consist essentially of, or consist of one or more
polyesters . In one aspect , the outer surface of the polymeric
nanoparticles can comprise, consist essentially of, or consist

of PCL .
In certain aspects , the polymeric nanoparticles can have a
maximum dimension of at least about 200 nm , at least about

removed by the polymeric nanoparticles based on the
change in fluorescence intensity levels of the samples
described above.
(Eq. 1 )

% endotoxin removal =
Fl of

100 x =

BC plus endotoxin plus NPs –

BC plus endotoxin

FI of ( BC plus NPs – BC alone)

In certain aspects, the polymeric nanoparticles can have
an endotoxin removal efficacy per unit surface area of the

polymeric
nanoparticle(s ) of at least about 3x10 endotoxin
ita
units
per www2f41
cm ? of the outer surface area of the polymeric
nanoparticles (EU /cm²), or at least about 1x10° EU / cm², or
about 1.49x10° EU /cm². The endotoxin removal efficacy per
unit
surface area of the polymeric nanoparticle ( s) can be
about 250 nm to about 600 nm , about 250 nm to about 500
calculated
using the fluorescence displacement assay
nm , about 300 nm to about 700 nm , about 300O nm
to about
about 2020 described above
nm
to
.
600 nm , or about 300 nm to about 500 nm . As used herein ,
In calculating the endotoxin removal efficacy per unit
maximum dimension refers to the maximum dimension of a outer surface area of the polymeric nanoparticle, the number
nanoparticle , which can include a maximum diameter, maxi of nanoparticles is first calculated according to Equation 2
m
mum
length , maximum width , or maximum depth . For below :
example , for a spherical polymeric nanoparticle , the maxi- 25
mum dimension would refer to the maximum diameter. In
another example , for a rod -shaped polymeric nanoparticle,
Number of polymer nanoparticles per ml = (6 W X1012) (Eq. 2 )
250 nm , or at least about 300 nm ; about 700 nm or less,
about 600 nm or less, or about 500 nm or less; or about 200
nm to about 700 nm , about 200 nm to about 600 nm , about
200 nm to about 500 nm , about 250 nm to about 700 nm ,

15

the maximum dimension refers the largest of the length ,
PXAX 3
In certain aspects , the polymeric nanoparticles can have a 30
substantially uniform size . In alternative aspects, the poly where, W is the concentration of polymeric nanoparticles in

width , and depth of the rod -shaped nanoparticle .

, p is the density ofpolymeric nanoparticles in g /ml, and
meric nanoparticles can have different sizes. In various wg /ml
is
the
diameter of the polymeric particles in um . It should
aspects, the polymeric nanoparticles can have a polydisper be understood
that these values can be determined by one
sity index value of about 0 . 05 , 0 .1 , 0 . 2 , 0 .3 , or 0 .4 .
35 skilled in the art using conventional techniques . For
In various aspects , the polymeric nanoparticles can be any
, the diameter of the particles or the average diam
shape or mixture of shapes . A non -limiting list of nanopar example
eter of the particles can be determined using transmission
ticle shapes includes sphere -shaped , rod -shaped , and disk electron microscopy ( TEM ), and / or Dynamic Light Scatter
shaped . In certain aspects, the polymeric nanoparticles can
ing (DLS ). The number of endotoxin units (EU ) per unit
be substantially one shape, such as approximately spherical. 40 outer surface area of the polymeric nanoparticles can be
In one or more aspects, the polymeric nanoparticles can calculated according to the following equation (3 ):
remove at least about 60 % of an endotoxin present in an

endotoxin - containing aqueous solution , at least about 65 % ,
at least about 70 % , or at least about 75 % . The % endotoxin
removal can be determined using any conventional molecu - 45
EU per unit outer surface area of polymeric nanoparticles =
lar techniques known to one skilled in the art. An exemplary

method for measuring the % endotoxin removal can include
the use of a fluorescent displacement assay, such as a
BODIPY -Cadaverine (BC )-based fluorescence assay using

E . coli 055:B5 endotoxin . As used herein BODIPY refers to 50

boron - dipyrromethene and is a commercially available fluo

( Eq. 3)

Total endotoxin removal by
nanoparticles per ml of test solution
(surface area of each nanoparticle)

(number of polymeric nanoparticles per ml)

rescence dye, for example , available at Sigma. In this assay,

the fluorescence intensity may be measured for given con
In various aspects , the polymeric nanoparticles can have
centrations of BC and the 055 : B5 endotoxin , or other
an endotoxin removal capacity of at least about 1. 5x107
endotoxins, in a particular sample prior to endotoxin 55 endotoxin units per gram of polymeric nanoparticle ( EU /g ),
removal and after endotoxin removal from the particular at least about 1x108 EU / g , at least about 1x109 EU /g , or at
sample . As endotoxins became bound to the surfaces of the least about 7x10° EU /g , or about 7.9x10° EU / g . The endo
polymeric nanoparticles, the endotoxins release BC causing toxin removal capacity can be determined by dividing total
an increase in the fluorescence intensity of BC . The change

endotoxin removal by nanoparticles per ml of test solution

in fluorescence intensity of BC can be determined using a 60 by the nanoparticle concentration in g /mL .

commercially available plate reader (Biotek ). To determine
the level of endotoxin removal by the polymeric nanopar -

ticles, the background fluorescence intensities of BC and

polymeric nanoparticle control (NPs), BC and endotoxin

In one or more aspects , the polymeric nanoparticles can
be synthesized in any manner known to one skilled in the art.

In certain aspects , the polymeric nanoparticles can be syn

thesized using a one -step phase separation technique. Gen

control, BC alone were subtracted to avoid any interfer - 65 erally , in such aspects , a solution of one or more polymers

ences . The endotoxin removal efficiency were determined by
Eq. 1, which calculates the amount ( % ) of endotoxin

in an organic phase can be precipitated out into an aqueous
phase .
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In various aspects, the phase separation technique can

various fluids, such as aqueous solutions. In various aspects,

organic solvent, such as toluene, into an aqueous solution . In
certain aspects , the aqueous solution can include additives ,

enhanced when the polymeric nanoparticles are associated
with one or more types of support members, such as a film ,

In certain aspects, the concentration of polymer in the
organic solvent can range from about 0 .1 mg/mL to about

ing to the polymeric nanoparticles . In the same or alternative
aspects , the supportmember may provide an efficient endo

include injecting a solution of one or more polymers in an

the versatility of the polymeric nanoparticles may be

such as surfactants , e . g ., polyvinyl alcohol. It is appreciated 5 membrane , or beads. In such aspects , the support member
that one skilled in the art understands that the concentration may enhance the binding of endotoxin to the polymeric
of polymer(s ) in the organic solvent, the injection rate of the nanoparticles through non -specific binding of the endotoxin
polymers into the aqueous solution , and / or the particular to the support member material, which can increase the local
components of the aqueous solution can be modified to
concentration of the endotoxin allowing for increased bind
achieve specific sized and shaped nanoparticles .

toxin separation mechanism by immobilizing the polymeric
1000 mg/mL , or from about 1 mg/mL to about 100 , or can
nanoparticles
so an endotoxin - free fluid or reduced -endo
be at least about 0 . 1 mg/mL , or at least about 1 mg/mL . In
certain aspects , the concentration of polymer in the organic 15 toxin fluid can flow through or past the immobilized poly
meric nanoparticles bound with endotoxin .
solvent can be about 10 mg/mL .

In one or more aspects , the flow rate or injection rate of

the organic solvent comprising one or more polymers into
the aqueous phase can range from about 0 - 1000 uL / sec .

An exemplary support member may include a film or

membrane . Commercially available films ormembranes are
suitable for use with the polymeric nanoparticles, such as

Without being bound to any particular theory, when using 20 cellulose films, or various types of filter paper. In such

the phase separation technique to make the polymeric nano -

particles, it is believed that the polymeric nanoparticles can
be formed by phase separation at the boundary where the
organic solvent slowly diffuses into the aqueous solution .

aspects , the polymeric nanoparticles may be embedded in

the film or membrane and /or can be affixed to at least one
exterior surface of the film or membrane.
In one exemplary aspect, a cellulose based nanoparticle

Further, without being bound to any particular theory, it is 25 film can be prepared by : 1 ) preparing a 50 : 50 solution of
believed that the polymeric nanoparticles can form by virtue
ethanol and isobutanol; 2 ) preparing a 20 % NaOH - deion
of van der Waals attractive forces between the individual ized water solution ; 3 ) weighing 20 g of alpha cellulose
polymer molecules under low shear stress . Stated differently, powder; 4 ) adding 200 ml ethanol-isobutanol solution ; 5 )
without being bound by any particular theory , as polymer mixing the cellulose mixture with stir bar at 900 rpm until

molecules start precipitating out of an organic phase into an 30 well-mixed (approx . 10 minutes ); 6 ) adding NaOH solution
aqueous phase, the molecules can accumulate and form
drop by drop until pH reaches 9 .0 ; 7 ) setting the solution in
spheres or other shapes under slow stirring conditions.
oven until temperature is 60° C .; 8 ) setting the stir bar to 900
FIG . 1 depicts an exemplary system 100 that can be

utilized to synthesize polymeric nanoparticles using a phase

rpm for 30 minutes in oven ; 9 ) adding sodium chloroacetic

acid drop by drop until the pH reaches 7 .0 ; 10 ) neutralizing

separation technique . The system 100 can include a syringe 35 and purify CMC solution with 20 ml of 96 % ethanol; 11 )

pump 102 for injecting one or more polymer -containing

adding polymeric nanoparticles; 12 ) pouring the liquid

solutions into an aqueous solution 106 housed in a vessel

through 40 um strainer onto an aluminum plate ; 13 ) spread

108 . A homogenizer 110 can also be positioned inside the

the liquid evenly on plate ; and 14 ) let sit over -night . It is

vessel 108 . It is appreciated that the components of this

appreciated that one or more alterations can be made to such

In certain aspects , polymeric nanoparticles may be made

a film or membrane 202 embedded with polymeric nano

concentration of polymer therein into an aqueous solution

toxin being exposed to the membrane 202 . In the system

system 100 are commercially available and well known to 40 a nanoparticle film preparation .
FIG . 2 depicts one exemplary filtering system 200 having
one skilled in the art.

by injecting an organic solvent having a predetermined

particles . FIG . 2 also depicts a fluid 204 containing endo

using a syringe pump, such as the syringe pump 102 of the 45 200 , the polymeric nanoparticles can bind to the endotoxin

system 100 of FIG . 1. In one aspect, the concentration of the

present in the fluid 204 . Since the polymeric nanoparticles

polymer can be 10 mg/mL , the polymer can include PCL ,

are immobilized on the membrane 202 , the remainder of the

an aspect, the aqueous solution can include about 1 % w / w

endotoxin -free or reduced endotoxin fluid 206 .

and the organic solvent can include toluene . Further, in such

polyvinyl alcohol. To form the polymeric nanoparticles , the 50

organic solvent and polymer solution can be delivered into
the aqueous solution at a predetermined rate with constant
stirring and/ or homogenizing, e .g ., using the homogenizer

fluid can pass through themembrane 202 thereby forming an

In alternative aspects , the polymeric nanoparticles may be

immobilized on the outer surface of beads, such as beads
comprising silica , silicon , cellulose , or a mixture thereof. It
is appreciated that one skilled in the art would understand

110 . In various aspects , the polymer dispersion may be

how to immobilize the polymeric nanoparticles on the outer

to remove any residual organic solvent by evaporation . After

e . g ., an ester or amine group .

homogenized using the homogenizer 110 at about 300 rpm 55 surface of the beads using conventional techniques . In one
for a predetermined period of time. The polymer dispersion exemplary aspect, the polymeric nanoparticles maybe cova
may be stirred continuously for an extended period of time lently attached via a functional group present in the polymer,

the residual organic solvent is removed by evaporation , the

In various aspects, both the beads and the polymeric

necessary with added water, for washing the polymeric

polymeric nanoparticles in order to remove endotoxin from

polymeric nanoparticles may then be separated from the 60 nanoparticles may be considered non -porous, such that an
aqueous phase by centrifugation , repeating this step as
endotoxin - containing fluid does not enter the beads or

nanoparticles from any residual organic solvents. Then , the

the fluid . This is unlike , for example, other various filtering

polymeric nanoparticles may be lyophilized , weighed , and
techniques, where the endotoxin -containing fluid may enter
65 pores or channels in a particle , and where the endotoxin gets
stored at a temperature of about 4° C .
As discussed above , in certain aspects , the polymeric
trapped and an endotoxin free fluid flows out of the pores or
nanoparticles can be utilized to remove endotoxins from
channels resulting in an endotoxin - free fluid .

US 9 ,918,943 B2
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In certain aspects , beads having polymeric nanoparticles
immobilized thereon may be loaded onto columns, car
tridges, or corks to be used in line with , for example, an IV
line, to remove any residual endotoxins in IV fluids that may

Characterization of PCL Nanoparticles — Shape,

300 can include a filtering device 302 having beads 304 with

Size , and Surface Charge
The shape and size of the polymeric PCL nanoparticles
prepared in Example 1 were analyzed by TEM ( Tecnai F20 )
at 120 kV. FIG . 4 shows a TEM image of a sample of the

in the path of the fluid flow such that the fluid 308 having
endotoxin flows through the filtering device 302, allowing at
least a portion of the endotoxin to bind to the polymeric

Example 1 provided nanoparticles having a maximum
dimension or maximum diameter of 398 . 3 + 95 . 13 nm in

meric nanoparticles may be immobilized on the inner sur

syringe filtered deionized water in concentrations of 0 , 10 ,

be potentially harmful for patients .
FIG . 3 depicts one exemplary filtering system 300 using
an inline filtering device for endotoxin removal . The system

5

polymeric nanoparticles immobilized on the outer surface of polymeric nanoparticles prepared as in Example 1 . As seen
the beads 304 . A fluid line 306 can include a fluid 308 having 10 in the TEM image in FIG . 4 , the polymeric nanoparticles are
endotoxin therein . The filtering device 302 can be positioned
substantially uniform in size and are approximately spheri

cal. The polymeric PCL nanoparticles prepared as in

nanoparticles present on the surface of the beads 304 , 15 large quantities .
thereby allowing a endotoxin - free or reduced endotoxin
size distribution and surface charge of the polymeric
fluid 310 to flow through the line 312 exiting the filtering PCLThenanoparticles
in water were measured by dynamic light
device 302
scattering
(
DLS
;
Malvern
NanoSeries Zetasizer ZS90 ).
In an embodiment not depicted in the figures
the poly
poly -- 202. Poly
res,, the
Polymeric nanoparticle suspensions were prepared in 0 .2 um
face of a fluid line so that as a fluid flows, the polymeric

100 and 1000 ug/ml. The suspensions were vigorously

nanoparticles can bind to endotoxin and thereby form an
endotoxin -free of reduced endotoxin fluid .

stirred for a minute and sonicated (Branson ). DLS measure
ments were performed at 25° C . in disposable capillary cells

From the foregoing, it will be seen that this invention is 25 (Malvern ) using the backscattering detection at 90°. The size

one well adapted to attain all the ends and objects herein
above set forth together with other advantages which are
inherent to the systems and methods.

distribution was obtained for 100 successive runs. The zeta

potential was measured for 15 runs. Data was analyzed using

means and standard deviations of the three concentrations.
FIG . 5A shows a graph of the size distribution of the
nations are of utility and may be employed without reference 30 polymeric nanoparticles by intensity . As seen in FIG . 5A ,
to other features and subcombinations . This is contemplated
there is a single peak that is consistent with an approximate
by and is within the scope of the claims.
diameter of about 300 nm to about 500 nm for the polymeric
Since many possible aspects may be made of the inven
nanoparticles produced as in Example 1 , and which confirms
tion without departing from the scope thereof, it is to be as the size distribution measured using TEM . The size distri
understood that all matter herein set forth or shown in the
bution was further confirmed by DLS with a polydispersity
accompanying drawings is to be interpreted as illustrative index of 0 .2 . The uniform size , as determined by both DLS
and not in a limiting sense.
and TEM , confirm that the polymeric nanoparticles did not
aggregate after drying and dispersing in suspension when
It will be understood that certain features and subcombi -

EXAMPLES

40 forming the nanoparticles as described in Example 1 .

FIG . 5B shows the zeta potential distribution , which
shows that the polymeric PCL nanoparticles produced as in
Example 1 are slightly negative at – 12 .438 .28 mv.

The concepts discussed herein will be further described in

the following examples , which do not limit the scope of the
various aspects described in the claims.

Each experiment in the below examples that included
quantified measurements was carried out in at least three
independent experiments with triplicate measurements. Data

45

Quantification of Endotoxin Removal by the

Polymeric Nanoparticles

were summarized using means and standard deviations.

Example 1
Synthesis of PCL Nanoparticles

50

5533

In this example , PCL nanoparticles were prepared by a
phase separation method. A 10 mg/mL PCL (Sigma) solution
in toluene was injected into a 1 % w /v polyvinyl alcohol
(PVA ) surfactant aqueous solution using a syringe pump (kD
Scientific ). The mixture was homogenized at 300 rpm . The 60
dispersion was stirred overnight at room temperature (~ 22°
C .) to remove residual toluene. The polymeric nanoparticles

were separated from the dispersion by centrifugation at

Example 3

A polymeric nanoparticle BODIPY-Cadaverine (BC )
based fluorescence assay was employed in order to deter
mine the endotoxin binding efficacy. E . coli 055 :B5 endo
toxin (Sigma) from E . coli bacteria was used as an
exemplary endotoxin in this assay .
exempl

First, an optimum mass ratio of BC and endotoxin was
determined. BC (Invitrogen ) was dissolved in dimethyl

sulfoxide (DMSO ; Sigma) to prepare a stock concentration

of 3 . 33 mg/ml. The excitation and emission wavelengths for

BC were 485 /20 and 528 /20 nm , respectively . The molar
ratio of BC and endotoxin was determined from quenching
of BC fluorescence intensity (F .I.) using a plate reader
(Biotek Synergy ) . BC of 262. 11 ug/ml was added to differ

4 ,600 rcf for 20 min . Particles were washed by centrifuga ent concentrations of endotoxin from 0 -50 ug/mlin DIwater
tion three times using deionized water. The resulting nano - 65 of pH - 7.4 at 25° C . in a 96 -well plate (Corning).

particles were lyophilized , weighed and stored at 4° C . until
further use.

FIG . 6 shows a plot of the fluorescence intensity of BC at

262. 11 ug/mL versus various endotoxin concentrations. In

US 9 ,918,943 B2
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the absence of endotoxins , BC exhibited the highest fluo
rescence intensity (1405 .2 - 322.2 ). The addition of endo
toxin to BC sharply decreased the fluorescence intensity of

BC , indicating fast binding and rapid saturation of BC with
endotoxin via quenching mechanisms. Addition of more 5
endotoxin beyond 50 ug/ml endotoxin increased the fluo

Example 4

Comparison of Endotoxin Removal Efficacy Per
Unit Surface Area

The efficiency of endotoxin removal per unit outer surface
compared with that reported for a commercially available

rescence intensity of BC indicating that there was an opti

area of the polymeric nanoparticles was calculated , and

mum BC :endotoxin working ratio of 5 . 24 w :W ratio . 50
ug/ml endotoxin were used to evaluate the binding efficiency

membrane (Pall). The calculations were done using Eq . 2 as

of endotoxin removal via the polymeric nanoparticles was

o is the diameter of the PCL nanoparticles in um . In the
present example , the number of polymeric PCL nanopar
ticles/ml was calculated for 50 ug/ml, which showed the

of the polymeric nanoparticles .
Using this BC :endotoxin working ratio , the quantification

described above, where, W is the concentration of nanopar
ticles in g /ml, p is the density of PCL polymer in g /ml, and

determined . Asmentioned above, the binding of endotoxin
highest endotoxin removal efficacy with a p of 1 . 146 g/mlat
assay. In this displacement assay , 50 ug/ml endotoxin was 15 25° C . and a particle diameter of q = 0 .398 um . Then the total

was determined using a BC fluorescence displacement
mixed with 262 . 11 ug /ml BC in 0 .6 ml deionized water

number of polymeric PCL nanoparticles and the total outer

(pH - 7 .4 ) in a 1. 5 ml centrifuge tube (Corning) . Serial
dilutions of polymeric PCL nanoparticles (made as above ) of

surface area of polymeric PCL nanoparticles in the final
volume of 0 .6 ml were calculated. These values appear in

0 , 0 .1 , 1 , 2 , 5 , 10 , 15 , 20 , 25 , 30 , 40 and 50 ug/mlwere added

Table 1, below .

TABLE 1
Endotoxin and nanoparticle values

PCL

nanoparticle

PCL

5 x 10 -5

1.146

Diameter of a

Endotoxin

PCL

nanoparticle,
PCL
Surface area/ Endotoxin removal
concentration
, nanoparticle
W
density , p
nanoparticles/ml nanoparticle concentration (EU /cm²
( g/ml)
(g /ml)
(um )
by Eq. (2)
( cm ~/ml) (EU /ml) nanoparticle )

0.3983

2.1 x 108

0.335

5 x 105

1.49 x 106

to the tube to measure endotoxin -binding efficiency . As

Finally , the number of EU per unit area of nanoparticles

endotoxins became bound to the surfaces of the polymeric

was calculated by equation 3 described above. The total

PCL nanoparticles, the endotoxins released BC causing an

endotoxin removal per unit outer surface area of polymeric

increase in BC fluorescence intensity . The change in fluo - 35 nanoparticle was 1.49x106 EU /cm2.
rescence intensity of BC was determined using the plate
The removal efficacy per unit outer surface area of the
reader (Biotek ). The background fluorescence intensities of polymeric nanoparticles (1 .49x106 EU /cm2) is 6 .7 fold more
BC and polymeric nanoparticle control, BC and endotoxin
control, BC alone were subtracted to avoid any interfer -

efficient than a commercially available hydrophobic charged
microporous membrane. A membrane that has a porous

ences . The % endotoxin removal efficiency of the various
concentrations of polymeric PCL nanoparticles were determined by Eq . 1 listed above. FIG . 7 shows a plot of the
percent endotoxin removal efficiency against the various
45
polymeric PCL concentrations.

hydrophobic polyether sulfone matrix , and polyamines
within thematrix (Pall Corporation) has been shown to bind
up to 2 .23x10 % EU /cm². Porous silica gel matrix with silica
particles showed endotoxin removal capacity of 1.2x107
EU /g , while PCL nanoparticles removed almost 655 times

When the polymeric nanoparticles were added to the
aqueous mixture of BC and endotoxin (5 . 24 w :w ratio ), the

more (7 . 9x10° EU / g ) endotoxin with an initial concentration
of 0 .5x10° EU /ml. Cellulose beads in an ETClean chromato
graphic column have been shown to provide a removal

polymeric nanoparticles competitively bound to endotoxin
displacing its binding with BC .As a result and as can be seen capacity of 4 .8x106 EU /ml. These results suggest that a
in FIG . 7 . the fluorescence intensity of BC increased from its 50 support based system could be utilized , such as embedding
quenched state in equilibrium with endotoxin with the the polymeric nanoparticles or affixing the polymeric nano
endotoxin binding to the polymeric nanoparticles . As bind particles to a support member as discussed above , to further
enhance the endotoxin removal capacity of the polymeric
ing increased between endotoxin and the polymeric nano
particles , the % increase in fluorescence intensity of BC also nanoparticles.
increased , indicating a proportional relationship between the
Example 5
two. The % increase in fluorescence intensity of BC was
used to calculate endotoxin - binding removal efficiencies of
Endotoxin -PCL Nanoparticle Binding as Imaged by
polymeric PCL nanoparticles by Eq . 1. PCL nanoparticles
TEM and Measured by Surface Charges
effectively removed up to 78 .78 28 . 84 % endotoxin .
60
The binding curve of FIG . 7 showed a two -step mecha TEM was used for high -magnification visualization of
nism reflecting the formation of initial endotoxin hitchhik endotoxin binding on polymeric PCL nanoparticles. 50
ing at low concentrations to multiple endotoxin hitchhiking ug/ml endotoxin was incubated with 50 ug /ml polymeric
to a single nanoparticle as the concentration reaches to
PCL nanoparticles produced as in Example 1 in a 1. 5 ml
saturation . Indeed , as described in Example 5 below , TEM 65 centrifuge tube for 10 min . 10 ul of the sample was put on
images (in FIGS. 8A and 8B ) show multiple endotoxin
top of a pre -wetted copper -carbon TEM grid ( Tedpella ),
molecules binding to the same polymeric nanoparticle .
air -dried for an hour and further dried in a desiccator until

US 9 ,918,943 B2
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being imaged by a TEM (Tecnai F20 ) at 120 kV . FIGS. 8A
and 8B are two TEM images showing how more than one
endotoxin molecule binds a single polymeric PCL nanopar

TABLE 3
Cost and Capacity Comparison of PCL

Nanoparticles and a Commercial Resin

ticle .

Endotoxin

Endotoxin binding was also confirmed by changes in
PCL mixture. Samples were loaded in pre - rinsed folded
capillary cells (Malvern ) for surface charge measurements
surface charges of endotoxin solution alone and endotoxin

Method
Polycaprolactone Nanoparticles

Price of Solution

Removal
(ng/ml)

$ 0 . 972/ml of solution

2.50E + 08

Thermo Scientific Endotoxin

$ 27 .20 /ml of solution

2 . 00E + 05

using a Nanoseries Zetasizer (Malvern ). A minimum of three 10 Removal Resin
individual samples was measured . FIG . 9A shows the zeta
potential distribution of pure endotoxin , which exhibits a
As can be seen in Table 3 , the PCL nanoparticles can
highly negative surface charge of - 27.76.1 mV that was

remove at least 103 more endotoxin permL of nanoparticles
compensated by the net negative charge of PCL nanopar compared
to a mL of commercially available endotoxin
ticles. After being hitchhiked on ( or bound to ) the nanopar- 15 removal resin
.
ticles , the net surface charge of endotoxins increased to
- 14 .7 + 3 .63 mV (as seen in FIG . 9B ), indicating a charge
What is claimed is:
overcompensation by polymeric PCL nanoparticle binding .
1. An endotoxin removal system , comprising :
20 a plurality of polymeric nanoparticles , each polymeric
Example 6
nanoparticle of the plurality of polymeric nanoparticles
having a maximum dimension between 300 nm and

500 nm ; and

Comparison of Endotoxin Binding to Nanoparticles
and Polymers

25

A fluorescence- based assay was utilized to compare the
endotoxin binding ability of PCL nanoparticles to various
polymers . As can be seen in FIG . 10A , the fluorescence
intensity of BODIPY decreases with increasing amounts of 30
endotoxin (e .g ., E . coli 055:B5 endotoxin ). It is believed that
the endotoxin binds to BODIPY and quenches the BODIPY

fluorescence signal. When the polymer or nanoparticles bind

to the endotoxin , the endotoxin is no longer free to bind to

BODIPY and quench the BODIPY fluorescence signal, thus 35

the level of the BODIPY fluorescence signal correlates with
the amount of polymer (or nanoparticle ) binding to endo

toxin (in the presence of BODIPY ) . FIGS . 10B - 10E depicts

a support member associated with the plurality of poly
meric nanoparticles , wherein , when an aqueous solu
tion comprising endotoxin molecules is exposed to the
endotoxin removal system , the supportmember and the
plurality of polymeric nanoparticles are cooperatively
configured to separate at least a portion of the endo
toxin molecules from the aqueous solution , and
wherein each polymeric nanoparticle of the plurality of
polymeric nanoparticles has an endotoxin removal
capacity of at least 1x10° endotoxin units per gram of
polymeric nanoparticle ( EU / g ).
2 . The endotoxin removal system of claim 1, wherein each

polymeric nanoparticle of the plurality of polymeric nano
particles has an endotoxin removal efficacy of at least 1x100

endotoxin units per cm of polymeric nanoparticle surface

the fluorescence intensity of BODIPY in the presence of area (EU / cm2).
varying concentration of various polymers ( FIGS. 10B , 10C , 40 3 . The endotoxin removal system of claim 1 , wherein each
and 10E ) or in the presence of varying concentrations of polymeric nanoparticle of the plurality of polymeric nano
PCL nanoparticles
cles (FIG . 10D ). Further, Table 2 below
particles comprises a polyester.
shows the maximum percent removal of endotoxin for the
4 . The endotoxin removal system of claim 3 , wherein the
various polymers of nanoparticles , which was calculated polyester comprises Poly ( e- caprolactone ) (PCL ).
based on the data in FIGS . 10A - 10E .
45 5 . The endotoxin removal system of claim 1, wherein the

support member comprises a film .

TABLE 2

6 . The endotoxin removal system of claim 5 , wherein the
film
comprises cellulose .
Comparison of Endotoxin Removal
7 . The endotoxin removal system of claim 1 , wherein the
Polymer or Nanoparticle
Maximum Percent Removal of Endotoxin 50 support member comprises a plurality of beads, the plurality
1 ,4 C - 1,4 Bis Polymer
EGDE -3 , 3' Polymer
PCL nanoparticles
Polyethyleneimine Polymer

of beads comprising silica , silicon , cellulose , or a mixture

72 %

thereof.

77 %

8 . A method for removing endotoxins from an aqueous

47 %

73 %
55

As can be seen in FIGS. 10B - 10E and Table 2, the

polymers show endotoxin binding at lower polymer con
centrations ( compared to the PCL nanoparticle concentra
tions for endotoxin binding). However, as can be seen in 60

FIG . 10D , the PCL nanoparticles can remove a high con
centration of endotoxin .
Material cost analysis shows that polymeric nanopar
ticles, e .g., PCL nanoparticles, offer a significantly greater
cost effectiveness. Table 3 shows a comparison of the costs 65
associated with endotoxin removal by PCL nanoparticles
versus a commercially available resin .

solution , the method comprising :
exposing an aqueous solution comprising endotoxin mol
ecules to polymeric nanoparticles so that at least a

portion of the endotoxin molecules bind to an exterior
surface of one or more of the polymeric nanoparticles

to form endotoxin -bound polymeric nanoparticles,
maximum dimension of about 300 nm to about 500 nm ,
and wherein each of the polymeric nanoparticles have
an endotoxin removal capacity of at least 1x10° endo
toxin units per gram of polymeric nanoparticle (EU /g );
and
removing at least a portion of the aqueous solution from
the endotoxin -bound polymeric nanoparticles.
wherein each of the polymeric nanoparticles has a
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9. The method of claim 8, wherein the polymeric nano
particles comprise a polyester.
10 . The method of claim 9 , wherein the polyester com
prises Poly ( e-caprolactone) (PCL ), polylactic acid (PLA ),
Poly (lactic - co -glycolic acid (PLGA ), hyaluronic acid (HA ), 5
poly (acrylic acid ) ( PAA ), poloxamers , polyethylene oxide

(PEO ), polyethylene glycol (PEG ), polyflutamic acid , or a
mixture thereof.
11 . The method of claim 8 , wherein the polymeric nano
particles are associated with a support member, wherein the 10
support member comprises one of a film or a plurality of
beads.

16
exposing an aqueous solution comprising endotoxin mol
ecules to polymeric nanoparticles so that at least a
portion of the endotoxin molecules bind to an outer
surface of one or more of the polymeric nanoparticles

to form endotoxin -bound polymeric nanoparticles,

wherein at least the outer surface of each of the
polymeric nanoparticles comprises Poly ( e -caprolac

tone) (PCL ), wherein each of the polymeric nanopar
ticles has a maximum dimension of about 300 nm to

about 500 nm , and wherein the polymeric nanoparticles

have an endotoxin removal capacity of at least about
1x10° endotoxin units per gram of polymeric nanopar
ticle (EU / g ) and an endotoxin removal efficacy of at
least 1x10° endotoxin units per cm² of nanoparticle

12 . Themethod of claim 11, wherein the support member
comprises the plurality of beads, wherein the plurality of
beads comprise at least one of silica , silicon , or cellulose . 15
surface area ( EU / cm²).
13 . Themethod of claim 8 , wherein each of the polymeric
16 . The method of claim 15 , wherein the endotoxin
nanoparticles has an endotoxin removal efficacy of at least
comprise an endotoxin from one or more Gram
1x10 “ endotoxin units per cm² of nanoparticle surface area molecules
negative bacterial species .
(EU / cm²).
14 . The method of claim 8, wherein the removing at least 20 17 . The method of claim 16 , wherein the one or more
a portion of the aqueous solution from the endotoxin -bound Gram negative bacterial species comprises E . coli.
18 . The method of claim 15 , wherein the polymeric
polymeric nanoparticles comprises flowing the at least a
are embedded in a film .
portion of the aqueous solution past the polymeric nanopar nanoparticles
19 . The method of claim 15 , wherein the polymeric
ticles when the polymeric nanoparticles are at least partly nanoparticles are coupled to beads.
immobilized by association with at least one of a film , a 25

membrane , or beads.

15 . A method for removing endotoxins from an aqueous

solution , the method comprising :

20 . The method of claim 15 , wherein at least a portion of
the polymeric nanoparticles are spherical.
*

*

*
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